Literature DB >> 21599866

Cardiovascular risk in diabetic end-stage renal disease patients.

Angela Yee-Moon Wang1.   

Abstract

Diabetes mellitus is the leading cause of end-stage renal disease (ESRD), accounting for 54% of all incident cases according to the US Renal Data System. These patients suffer an extremely high mortality rate due to the very high incidence of cardiovascular disease. A significant proportion of these patients already has established cardiovascular disease at the time of initiation of dialysis treatment. More importantly, as these patients develop progressive kidney dysfunction, they are not only subjected to traditional Framingham risk factors, but, more importantly, to a whole host of "kidney disease-related risk factors" that further accelerate the progression of cardiovascular disease and thus contribute to adverse cardiovascular outcomes. The present article provides an updated view on the multitude of traditional Framingham risk factors and kidney disease-related risk factors that diabetic ESRD patients are subjected to. A better understanding of the different cardiovascular risk factors will be fundamental to institute early detection programs, as well as to provide aggressive cardiovascular management of these patients.
© 2011 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21599866     DOI: 10.1111/j.1753-0407.2011.00113.x

Source DB:  PubMed          Journal:  J Diabetes        ISSN: 1753-0407            Impact factor:   4.006


  7 in total

1.  Access to renal transplantation in the diabetic population-effect of comorbidities and body mass index.

Authors:  Bhanu K Patibandla; Akshita Narra; Ranil DeSilva; Varun Chawla; Alexander S Goldfarb-Rumyantzev
Journal:  Clin Transplant       Date:  2012 May-Jun       Impact factor: 2.863

2.  Inflammation Drives Stiffness Mediated Uptake of Lipoproteins in Primary Human Macrophages and Foam Cell Proliferation.

Authors:  Manasvini Ammanamanchi; Melanie Maurer; Heather N Hayenga
Journal:  Ann Biomed Eng       Date:  2021-11-03       Impact factor: 3.934

3.  Renal Outcomes of Pioglitazone Compared with Acarbose in Diabetic Patients: A Randomized Controlled Study.

Authors:  Yu-Hsin Chen; Der-Cherng Tarng; Harn-Shen Chen
Journal:  PLoS One       Date:  2016-11-03       Impact factor: 3.240

4.  The Impact of Diabetes Mellitus on Vascular Biomarkers in Patients with End-Stage Renal Disease.

Authors:  Jeonggeun Moon; Chan Joo Lee; Sang Hak Lee; Seok Min Kang; Donghoon Choi; Tae Hyun Yoo; Sungha Park
Journal:  Yonsei Med J       Date:  2017-01       Impact factor: 2.759

5.  Vitamin D3 ameliorates podocyte injury through the nephrin signalling pathway.

Authors:  Ourania Trohatou; Effie-Fotini Tsilibary; Aristidis Charonis; Christos Iatrou; Garyfalia Drossopoulou
Journal:  J Cell Mol Med       Date:  2017-06-29       Impact factor: 5.310

Review 6.  The Incidence of End-Stage Renal Disease in the Diabetic (Compared to the Non-Diabetic) Population: A Systematic Review.

Authors:  Maria Narres; Heiner Claessen; Sigrid Droste; Tatjana Kvitkina; Michael Koch; Oliver Kuss; Andrea Icks
Journal:  PLoS One       Date:  2016-01-26       Impact factor: 3.240

7.  Serum Carnosinase-1 and Albuminuria Rather than the CNDP1 Genotype Correlate with Urinary Carnosinase-1 in Diabetic and Nondiabetic Patients with Chronic Kidney Disease.

Authors:  Angelica Rodriguez-Niño; Sibylle J Hauske; Anna Herold; Jiedong Qiu; Jacob van den Born; Stephan J L Bakker; Bernhard K Krämer; Benito A Yard
Journal:  J Diabetes Res       Date:  2019-12-24       Impact factor: 4.011

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.